Pure Global: Brazil's ANVISA RDC 751 - Navigating the Hidden Post-Implementation Hurdles.

This episode of LATAM MedTech Insights dives deep into the lingering challenges of Brazil's landmark medical device regulation, ANVISA RDC 751. Years after its implementation, we explore the real-world operational hurdles that international MedTech companies continue to face, moving beyond the basics to uncover the hidden complexities in risk classification, technical documentation, and post-market surveillance. We analyze the costly surprises that arise from device reclassification. For instance, a manufacturer of orthopedic implants saw their product up-classified from Class II to Class III, triggering unexpected requirements for extensive, local clinical data. This single issue delayed their market entry by over a year and added hundreds of thousands of dollars in unplanned expenses, a critical pain point for any company looking to expand into Latin America's largest market. Key Questions Answered in this Episode: - Is your device's risk class under RDC 751 secretly jeopardizing your launch timeline? - How can you manage the intensive new Technical Dossier requirements without draining resources? - What are the most common post-market surveillance mistakes companies are making in Brazil? - Why is your choice of a Brazil Registration Holder (BRH) more critical than ever? - Are you prepared for ANVISA's increased scrutiny on clinical data for medium-risk devices? - How does Brazil's harmonization with global standards create both opportunities and traps? Pure Global offers end-to-end regulatory consulting solutions for MedTech and IVD companies. We combine local expertise with advanced AI and data tools to streamline your global market access, ensuring you navigate complex markets like Brazil with confidence. For a strategic partner in your global expansion, contact us at [email protected] or visit https://pureglobal.com/.